Seeking Alpha

With Androxal risk reduced, Repros Therapeutics has big upside: Brean

  • Count Brean's Jonathan Aschoff among the Repros Therapeutics (RPRX) bulls.
  • Today's Androxal news derisks the company's main asset, Aschoff notes, reiterating a Buy rating on the shares.
  • Brean's price target is hiked to $41 (from $32) which represents a 72% upside on top of Tuesday's double-digit gains.
  • "A full response from the FDA is expected in November to address RPRX's request regarding Priority Review," Aschoff adds.
  • RPRX had a strong session Tuesday, but trimmed early gains after theStreet's Adam Feuerstein raised a laundry list of concerns.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: